Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
French participants in the Tour de France between 1947–2012 lived longer than their same-age French counterparts.
AMSTERDAM, The Netherlands – French participants in the Tour de France between 1947–2012 lived longer than their same-age French counterparts according to the results of a study marking the centenary of the race this year.
“In the context of recent concerns regarding performance-enhancing techniques and the potential negative health effects of excessive high-level physical activity, data on the long-term outcomes and causes of death in elite endurance cyclists is of particular interest,” said Xavier Jouven, MD, PhD, from the Sudden Death Expertise Center in Paris, France.“Although our results are reassuring to some extent, since no death has been observed since 1990, we have to remain careful since we cannot directly assess the potential harmfulness of doping through our analyses and results.”
The study assessed 786 French cyclists who participated at least once in the Tour de France between 1947 and 2012, and compared them to the general French male population of the same age.
The cyclists had participated in a median of 2.5 Tour de France races and were followed for a median of 37.4 years. Their median age at the first race was 25 years.
A standardized mortality ratio (SMR) was calculated based on the actual death rate of the cyclists compared to the death rate in the age-matched French population according to the Human Mortality Database.
An SMR lower than 1 indicates the cyclists had a lower mortality rate than the general population, whereas an SMR greater than 1 indicates higher mortality.
The study found that of the 786 cyclists, 208 (26%) had died by September 01, 2012 – an SMR of 0.59 and a mortality rate that is 41% lower than the general population, said Dr. Jouven.
The two main causes of death for the cyclists were neoplasms (32.2%), and cardiovascular diseases (29%), both occurring less frequently than in the general public (SMRs of 0.56 and 0.67 respectively).Among cancers, the 3 main diagnoses were digestive (35%), lung (22%), and prostate (7%). For the third highest cause of death (15.8%), classified as “external” (mostly trauma-related) the SMR was 1.06 indicating about the same rate as in the general public.Other causes of death included infectious diseases (2.2%), endocrine and nutritional diseases (2.2%), neurological (2.2%), digestive system diseases (2.2%), and genitourinary disease (1.1%). The cyclists’ SMR was consistent across different periods of participation, corresponding to the reported or suspected use of cocaine and amphetamines (1947-1970), androgens and anabolic steroids (1971-1990) and growth hormone and erythropoietin (1991-2012), said Dr. Jouven.
The SMRs were also consistent across all age groups, except for the age-group younger than 30 years in whom a non-significantly higher death rate was observed (SMR 1.65) compared to the general population.
“A particularly high frequency of traffic or race accident deaths were seen in this age-group,” he said.
FUNDINGPrimary Funding Source: Institut National de la Santé et de la Recherche Médicale (INSERM) and Institut de Recherche BioMédicale et d'Épidémiologie du Sport (IRMES)
DISCLOSURES:The authors declare no competing interests.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2013. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.More information on the ESC Press Conference page: Hot Line IV: Late Breaking Trials on Heart Failure and Acute Coronary Syndrome
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2013The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information on ESC Congress 2013 contact the ESC Press Office.
© 2017 European Society of Cardiology. All rights reserved